Saturday 17 October 2026
Export ANL’s income statement to Excel — free account
Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023. Dividend growth for five consecutive years.
11.07
1.02
−8.44%
Follow ANL
Adlai Nortye Ltd. Sponsored ADR (ANL) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CADL Candel Therapeutics, Inc. compare | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| MDXG MiMedx Group, Inc compare | 111× |
| ANL Adlai Nortye Ltd. Sponsored ADR | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)